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Abstract
To better understand the extent of diagnostic and referral delays from primary care providers (PCPs) for chronic hematologic
malignancies, causes of these delays, and their possible effects on cancer outcomes, an extensive review of the literature was
performed. Over 50 studies were reviewed, including many that concern delays in referral and diagnosis for solid tumors, as
there was only sparse literature on delays specific to the liquid tumors. Delays for some chronic hematologic malignancies
have been documented, mainly in centralized health care systems. Possible reasons for delays include PCPs’ lack of exposure
to hematologic malignancies, limited knowledge of associated signs and symptoms, and a reliance on patient symptoms to
prompt referral (as opposed to signs and screening). Patient characteristics such as age, gender and race-ethnicity are also
likely to play a role, although it is unclear if these exert their effect primarily via patient or provider mechanisms.
Unfortunately, the outcomes associated with such delays are largely unreported, possibly because delay is complex to define
and difficult to measure.
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Introduction
The primary care provider (PCP) is frequently the
first point of medical contact for patients with
malignancy, and as such, serves a critical role in
facilitating cancer diagnosis and treatment. Although
guidelines for screening common malignancies such
as breast, colon and cervical cancer help in this effort,
hematologic malignancies are comparatively rare and
often present with subtle signs and symptoms.
Consequently, they pose a unique problem for the
PCP. This is especially true of the chronic hemato-
logic malignancies such as chronic lymphocytic
leukemia (CLL), chronic myeloid leukemia
(CML), myelodysplastic syndrome (MDS), multiple
myeloma (MM) and certain indolent types of non-
Hodgkin lymphoma (NHL).
Concerns about delays in diagnosis and referral for
cancer patients are not new. An early (1974)
descriptive study using interviews with cancer patients
and their families defined just three steps considered to
be the ‘ideal’ pathway for patients to attain definitive
oncologic care; some patients experienced excessive
delays, defined as one or more extra steps (e.g. referral
to an additional clinical expert) [1]. A later descriptive
work by Richard Wender categorised barriers to
optimal cancer detection by PCPs into three cate-
gories: ‘practitioner-based’ (e.g. lack of knowledge,
financial disincentive to refer), ‘patient-based’ (e.g.
fear about seeing physician, financial barriers to
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receiving care), and ‘health care system-based’ (e.g.
lack of specialists, lack of government support) [2].
Whatever the source of delay, timeliness of care
has become a priority, and was identified as one of six
aims of quality improvement in the Institute of
Medicine’s 2001 Crossing the Quality Chasm report
[3]. The report identified significant delays in all
aspects of care delivery, including access to appoint-
ments, prolonged responses to diagnostic findings,
and overdue implementation of therapeutic interven-
tions. The literature regarding solid tumors has
indeed documented delays in referral and diagnosis
for many cancers in both children and adults [4–9],
linking them to the frequency of cases experienced by
PCPs in clinical practice [10–13], as well as deficits
in knowledge regarding screening and diagnosis
[12,14]. In addition, delays in referral and diagnosis
have been shown to have a possible negative effect on
the outcomes associated with some solid tumors
[15,16]. In contrast, little research has focused on
hematologic malignancies, despite the fact that
improved techniques for pathologic diagnosis, sta-
ging, prognostication and therapy may translate into
significant benefits for patients who are referred and
diagnosed in a timely manner.
Our aim was to describe a possible problem
regarding referral and diagnosis of patients with
hematologic malignancies. We focused on the
chronic hematologic malignancies, as we reasoned
that their insidious nature would make them the most
susceptible to significant delays. We also aimed to
determine what is known about how such delays
might affect disease-related outcomes, as well as
present a sample of findings regarding the etiology of
delays for two common solid tumors (breast and
colon) and suggest how these factors may or may not
manifest for chronic hematological malignancies.
Finally, we aimed to present a research agenda for
further study informed by our literature review.
Methods
To identify relevant articles, we searched the
PubMed, EMBASE and Social Sciences Citation
Index databases. Search terms used included: ane-
mia, breast cancer, colon cancer, delayed diagnosis,
diagnostic delay, family physician, general practitioner,
hematologic malignancies, leukemia, lymphadenopathy,
lymphoma, multiple myeloma MM, myelodysplasia,
pancytopenia, presentation of cancer, primary care
physician, referral patterns, splenomegaly and alternate
synonyms in various combinations. We also searched
the abstracts presented at the most recent three
meetings of the American Society of Hematology.
We first used the subject headings in each database
followed by keyword searches. Promising abstracts
were reviewed, and a subset of those were retrieved
for in-depth review (read in their entirety by one or
more authors). Several articles were also selected to
undergo second-order searches for relevant publica-
tions through their references cited. Our initial
search strategy yielded 144 studies possibly relevant
for inclusion; upon detailed review, 56 of these were
deemed appropriate to include in this manuscript.
Although few studies assessed barriers to referral and
diagnosis specifically for the hematologic malignan-
cies, several addressed such barriers for solid-tumors,
as well as factors limiting PCPs’ practice of cancer
prevention and screening. Of note, no study speci-
fically addressed these topics for CLL or MDS.
Findings from literature review
Delays in diagnosis and referral for hematologic
malignancies
An important issue with all studies of delays in
diagnosis and referral is how ‘delay’ is conceptua-
lised, especially given the diverse and complex
pathways that patients take to treatment [17]. For
example, delays can occur due to patients’ failure to
see a provider in a timely manner, providers’ failure
to quickly refer patients to specialists, and specialists’
failure to quickly administer treatment; each of these
types of delay is likely to have its own covariates [18].
In addition, the way that delay is measured can
certainly affect outcomes, as very different assess-
ments of delay may be attained through surveying
physicians, surveying patients, reviewing medical
records or utilising large databases. Different assess-
ments can further be confounded by issues such as
recall bias and quality of documentation [9]. Finally,
the time period that is considered an unacceptable
delay is variable (e.g. from 2 weeks to 3 months) [15]
and can affect how delays interact with outcomes.
In addition, making comparisons between delays
for different cancers can be difficult, unless several
tumor types are presented in the same study. To that
end, a series of manuscripts has analysed data from
the United Kingdom’s National Health Service
(NHS) regarding delays in diagnosis for patients
with six cancers including NHL [9,19,20]. The total
duration of diagnostic delay (defined as first symp-
tom until definitive diagnosis) varied by cancer, with
breast cancer patients experiencing the shortest mean
delay (55 days), NHL patients falling in the middle
(103 days) and prostate cancer patients experiencing
the longest delay (149 days). The authors concluded
that the comparatively straightforward presentation
of a disease such as breast cancer may combine with
an increased public awareness of the same to lead to
comparatively shorter delays.
























































In the NHS study, patients who saw their PCP
prior to diagnosis experienced longer delays than
those who presented directly to a specialist [9,19]. In
a subsequent analysis of the entire cohort of patients
[20], longer delays were experienced by women,
younger patients, those with lower socioeconomic
status, those who were of black or south Asian
descent, and those who were unmarried. Most of
these patient factors had no apparent effect on
diagnostic delay for patients with NHL, except age;
those NHL patients younger than 25 and over
75 years old experienced total delays of 63 and
85 days, respectively, whereas NHL patients 45 to
54 years old experienced a total diagnostic delay of
128 days.
In another British study (retrospective chart
review) review of delays in diagnosis and treatment
for 89 NHL patients presenting to a regional
hospital, ‘patient delay’ (symptom onset to time
patient sought medical advice) accounted for the
most time passed between symptoms and treatment
(a mean of 3.9 months), compared with ‘diagnostic
delay’ (time from seeking medical advice to time of
diagnostic biopsy, 2.8 months), and ‘treatment delay’
(diagnostic biopsy to start of treatment, 1.2 months)
[21]. Delays were not affected by the location of
treatment clinic or by NHL subtype. A more recent
chart review of 194 British NHL patients showed that
on average, over a year elapsed between the onset of
symptoms and the beginning of treatment [22].
Here, delays to treatment did vary by lymphoma
type, as patients with more aggressive disease (e.g.
diffuse large B-cell lymphoma) experienced shorter
delays than those with more indolent disease (e.g.
follicular lymphoma).
A retrospective study of 116 Canadian patients
with NHL yielded an average of 137 days from the
onset of symptoms to start of treatment, with the
time before diagnosis constituting the largest propor-
tion of total delay. Males and patients with sympto-
matic ‘B-symptoms (i.e. fever, weight loss and night
sweats) had shorter delays. Patients in middle age
groups experienced longer delays than patients on
either extreme of the age spectrum. For all patients,
once a diagnosis was made, only 18 days passed
before the initiation of treatment, compared with
110.5 days from symptom onset to pathologic
diagnosis [23].
Interestingly, although the above literature docu-
ments significant delays in diagnosis for some
hematologic malignancies, not all studies argue that
PCPs should be more aggressive with regard to
referral. A Dutch retrospective chart review of 82
patients who presented to their PCPs with lympha-
denopathy found that although PCPs referred 90% of
patients ultimately found to have malignancy within
4 weeks, a high proportion of patients with benign
disease (68%) were also referred within 4 weeks. The
authors suggested that PCPs should be less liberal
with referrals because benign cases were being
referred nearly as often as malignant cases [24].
On the other hand, presentation for chronic
hematologic malignancies can be subtle, and deter-
mining the appropriate level of suspicion can be
difficult. In a retrospective chart review of 1027
patients diagnosed with MM, patients often pre-
sented with non-specific signs and symptoms such as
anemia (73%), anemia-related fatigue (32%) and
weight loss (24%) [25]. In a Dutch population-based
registry of 127 patients with MM [26], the disease
was not part of the initial differential diagnosis for
37% of patients; yet, of those, 51% had advanced
disease (stage III) at diagnosis, suggesting that the
absence of symptoms does not imply early-stage
disease. Interestingly, a recent analysis of patients
with MM in the Surveillance, Epidemiology, and
End Results (SEER) registry, from an analytic
sample of 5185 patients, found that patients with
higher comorbidity had a higher adjusted likelihood
of diagnostic delay [defined as greater than the
median time (98 days) between initial claim for
anemia or back pain], perhaps representing the
difficulty of diagnosing patients with non-specific
symptoms in the setting of substantial comorbidity
(OR 1.17, 95% CI: 1.03–1.33) [27].
Like MM, CML can also present with subtle signs
and symptoms. A review of the records of 430
patients with CML who had undergone allogeneic
bone marrow transplantation found that 20% were
diagnosed incidentally, as a result of a routine blood
test or due to the discovery of splenomegaly on
routine physical examination [28]. In another review
of 341 CML patients, 40% of those diagnosed after
1985 were asymptomatic at the time of diagnosis
compared with less than 20% diagnosed before that
time [29]. Such increases in asymptomatic diagnoses
may be the result of an increased use of routine blood
tests in current practice, but begs the question: does
detecting patients earlier improve disease-related
outcomes?
Do referral and diagnostic delays for chronic hematologic
malignancies affect outcomes?
For malignancies such as colon and breast cancer, a
delay in referral has been shown to lead to the
diagnosis of a more advanced stage of cancer
[15,16,30–33], but whether or not this translates to
worse outcomes is less clear [15,30,33–36]. The
ultimate effects of delays in diagnosis are even less
understood for the hematologic malignancies. Stu-
dies that specifically assess the outcomes associated
























































with diagnostic delays for this population are rare,
perhaps because lack of swift diagnosis and expedi-
tious treatment for aggressive malignancies such as
acute myeloid leukemia and Burkitt lymphoma are
known to lead to rapid death. Given the many tasks
PCPs are already expected to perform, it will be
difficult to motivate them to be more vigilant about
surveillance for and diagnosis of chronic hematologic
malignancies without clear evidence that early
diagnosis saves lives (such as that which exists for
several other types of cancers) [37–39].
A few studies provide preliminary insight. First, in a
review of 50 Norwegian patients with Hodgkin
lymphoma (HL) treated between 1985 and 1993, a
median of 4 months was found to have elapsed between
the first symptoms of HL and histological or cytological
confirmation [40]. Within 6 months, 78% of cases had
a verified diagnosis, and there was no relationship
between delay in diagnosis and stage of disease, relapse
rate, or overall survival. Second, especially for indolent
NHL, an upfront ‘watch and wait’ strategy is often
appropriate, and may thus diminish the value of rapid
referral and diagnosis. Indeed, a review of 92 patients
with low-grade NHL found that those whose treatment
was intentionally delayed at diagnosis experienced the
same survival as those who received immediate
treatment [41]. On the other hand, a recent case
review of 92 patients with MM showed that a
prolonged time to diagnosis (duration of symptoms
46 months) had a significant effect on disease-free
(but not overall) survival (p¼ 0.043) [42].
Delays in referral and diagnosis for solid tumors: Lessons
for the hematologic malignancies
As PCPs are responsible for requesting specialist
consultation for patients with suspected malignancy,
it is important to understand the factors that
influence their referral behavior. Although cancers
are often first noticed when patients present with
symptoms [11,43], with aggressive screening, it
stands to reason that PCPs can find more asympto-
matic cases [11]. Still, a large number of referrals for
oncologic genetic testing and counseling are patient
driven [44], and referrals from PCPs often do not
meet criteria established by expert panels for screen-
ing and referral [44,45].
PCPs’ oncology knowledge may be inadequate. For
example, an Italian survey of 134 family doctors, 31
general surgeons and 33 internists utilising treatment
vignettes found that less than half of the physicians
surveyed selected appropriate adjuvant chemotherapy
for colon cancer or any chemotherapy as first-line
treatment for small-cell lung cancer [12]. One might
expect PCPs to be even less able to diagnose and
manage hematologic malignance given their rarity;
indeed, in a recent American survey of 357 PCPs, only
22% said that they were confident educating patients
about hematologic malignancies, and only 10%
reported having ordered blood tests for monoclonal
gammopathy of undetermined significance (MGUS)
and MDS [46]. In recent years, there has been
remarkable growth in prognostic indicators and
therapeutic options for patients with chronic hemato-
logic malignancies, and PCPs’ lack of awareness of
these advances may also affect timeliness of referral.
PCPs sometimes have unfounded confidence in
their abilities to detect cancer. In a study of ovarian
cancer screening, 56% of PCPs felt qualified to
interpret genetic test results despite ‘considerable
variability’ in a standardised assessment of their
understanding of common risk factors [47]. In
addition, although one would expect a perceived lack
of familiarity with cancer diagnoses to be associated
with timely referral, this relationship is not always
consistent. For example, despite reporting rare ex-
posure to melanoma, 60% of surveyed PCPs rarely or
never referred patients with suspicious pigmented
lesions to specialists, preferring to excise such lesions
themselves [13]. Finally, beyond actual or perceived
knowledge, other PCP factors may play a role. As an
example, one study found that PCPs reviewing
hypothetical lung cancer vignettes were most likely to
suspect malignancy when patients experienced clinical
deterioration, had family members who insisted on
consultation, or when another primary care colleague
provided an informal opinion suggesting referral [48].
The literature regarding solid tumors also suggests
that PCPs are more likely to refer patients to
specialists in the presence of abnormal symptoms
rather than abnormal signs, laboratory results or
imaging. For example, a prospective study of 159
Italian PCPs found that patients referred for colono-
scopy were at least twice as likely to have reported
abdominal pain and bloating than to have had
laboratory evidence of iron deficiency anemia, even
though the latter was much more predictive of colon
cancer [49]. Likewise, a review of surgical referrals
for colorectal cancer in the United Kingdom showed
that although delays from symptoms to surgical
treatment improved between 1978 and 1988 overall,
the improvement was minimal for patients with right-
sided cancer [50]. This may be because right-sided
disease is traditionally more difficult to diagnose due
to fewer symptoms and more subtle presentation
(such as isolated mild anemia).
In breast cancer, patient symptoms may also lead
to quicker referral. In a cohort of 146 patients with
suspicious breast lesions, the mean time between
awareness of diagnostic need and completion of
diagnosis was 68.4 days for women with palpable
masses compared with 71.9 days for those referred
























































due to an abnormal mammogram [8]. Similarly, at a
London breast clinic, compared with those without,
women with breast lumps experienced less patient
delay as well as ‘system delay,’ defined as the time
between a women’s first medical contact and her first
consult with a breast specialist [51].
The above literature regarding symptoms and
signs for solid tumors has potential relevance to
patients with chronic hematologic malignancies. It
might follow that patients with hematologic malig-
nancies who exhibit only mildly abnormal laboratory
results but no obvious symptoms might be less likely
to be referred to specialists than patients with no
abnormal laboratory results but symptoms suggestive
of malignancy (e.g. night sweats, fever, or palpable
lymph nodes). Such PCP behavior may ultimately
make sense, as patients with chronic hematologic
malignancies who are asymptomatic may do well
without treatment despite their laboratory abnorm-
alities; however, it also may be true that patients with
hematologic malignancies who are diagnosed in the
setting of obvious symptoms respond less well to
treatment (e.g. MM patients with bone fractures).
PCPs may also be influenced by patient demo-
graphic characteristics, although when delays are
associated with these characteristics, it is uncertain if
they are ultimately due to patient or provider effects.
For example, patient insurance status has been
correlated with delays in cancer diagnosis for young
adults and older adolescents with cancer [52], but
whether the delay stems from patient or physician
behavior is unclear. A German study of rectal cancer
patients found that patients on welfare had greater
treatment delays (399 days) as compared with those
with supplemental insurance (107 days), with patient
delay (first symptoms to first physician contact)
comprising the majority of the total delay [53].
Whether such delays for patients of lower socio-
economic status are primarily due to patient delays in
seeking care (due to issues such as access to
transportation or inability to miss work) or PCP
delays in arranging care is unclear; however, it is
reasonable to assume that such factors may also play
a role in referral for patients with chronic hematolo-
gic malignancies.
Other patient factors such as age, sex, race-
ethnicity and education may act as covariates of the
likelihood of referral [18,54,55]. For example, in a
population-based study using data from the SEER
registry, African-American women, compared with
Caucasian women, had a longer diagnostic delay
(time from initial consult to biopsy confirming the
diagnosis), and represented the population with the
highest proportion having a delay of over 2 months
[56]. In the same registry, most women, regardless of
race, were treated within 3 months of their first
medical contact; however, a greater proportion of
African-American women had a delay of more than 3
months before start of treatment compared with their
Caucasian counterparts (22.4% vs. 14.3%, respec-
tively) [57]. The effect of race-ethnicity on breast
cancer referral and diagnostic delay has not been
uniformly observed, however [36,54], and its possi-
ble role in delays for hematologic malignancies is
currently unknown.
A patient’s fear of being diagnosed or having to
undergo a diagnostic test may also cause delays in
referral or diagnosis. For example, one group
found that the majority of delays in colon cancer
diagnoses took place between the onset of patient
symptoms and PCP office visit (112 days) [49].
The time between PCP visit and colonic investiga-
tion was considerably shorter (16 days), suggesting
that patient delay may constitute the most sig-
nificant factor contributing to referral and diag-
nostic delay. Indeed, another study of colorectal
cancer patients found that 50% reported fear of an
unpleasant investigation as a major reason for not
seeing their PCP sooner [53]. How such results
may be applied to patient delays for hematologic
malignancies is uncertain, because, given their
rarity, most patients are unlikely to be aware of
the diseases’ associated signs, symptoms and
diagnostic procedures.
Areas for further research
Our review identified few studies that examined
delays in referral or in diagnosis for chronic
hematological malignancies; however, based on the
studies we reviewed, as well as the related studies for
other tumor types, we pose a set of research
questions to aid our understanding of these phenom-
ena and lay the groundwork to potentially improve
outcomes for patients with these diseases. First, a
critical gap in our understanding is the determination
of clinically significant delays in referral or diagnosis
for chronic hematologic malignances. Although some
studies have described the average amounts of time
patients spend in phases of diagnostic work up,
referral, and treatment, it is important to understand
which delays are specifically associated with adverse
outcomes. Here, rigorous and reproducible defini-
tions of delay are essential. Second, determining
the impact of delays in differently financed and
managed health care systems would help identify
which policy initiatives appear to improve timeliness
of care and could be considered models for adoption
by other countries. For the United States, both of
these questions might be answered by utilising
known high-quality data sources such as SEER-
Medicare.
























































Finally, the literature we reviewed contained
widely inconsistent approaches to measurement,
study design, and data analysis which reduced the
ability to make meaningful conclusions. In addition,
certain diseases such as CLL and MDS have been
completely ignored. Studies that combine data
collected on practitioners and diverse patient popula-
tions, coupled with data from utilisation claims and
tumor registries are sorely needed. Again, attempts
should be made to standardise measures (such as
socioeconomic status of patients and practitioner
credentials) to enable comparisons across settings.
Armed with studies that address these knowledge
gaps, intervention research to reduce the adverse
outcomes of clinically significant delays in affected
patient populations would stand the best chance for
efficacy.
Conclusions
Although the overall literature on delays in referral
for hematologic malignancies is sparse, we did find
significant delays reported for referrals for NHL and
MM. Less clear is whether such delays ultimately
affect outcomes for hematologic malignancies, and
how to possibly ameliorate them. We explored
many possible reasons for diagnostic and referral
delays for hematologic malignancies by assessing
reported sources of such delays for the solid tumors.
Lack of PCP exposure to and knowledge of the
chronic hematologic malignancies as well as possible
biases due to patient characteristics (such as gender,
extremes of age, and race-ethnicity) all likely play a
role. The solid tumor literature suggests that
patients who present with symptoms are more likely
to be referred than those who are asymptomatic,
and patient delay in seeking care also seems
important.
The To Err is Human report by the Institute of
Medicine specifically identified delays in diagnosis as
a contributor to the so-called quality gap in the
American health care system [58]. We found scant
research into system issues such as lack of available
specialists, or incomplete follow-up after a referral
has been arranged (the completed ‘pass-off’). Indeed,
a recent review of literature focusing on follow-up of
abnormal screening findings found that most studies
detail only patient factors, with a severe lack of data
on the systems and practice issues involved in
assuring that a patient with suspected malignancy
actually gets from a PCP to a specialist in the setting
of an intended referral [59]. Problems here might be
highly amenable to centralised intervention, with
strategies such as internet-based communication,
automated clinical information and clinical decision
support systems.
Some studies of delay in lymphoma diagnosis hint
that, although patients with hematologic malignan-
cies may experience delays in diagnosis and treat-
ment, such delays may not result in compromised
outcomes [40,41]. On the other hand, as modern
oncologic treatments (e.g. targeted therapy for CML
and NHL) and molecular prognostic tools (e.g.
fluorescent in situ hybridisation for cytogenetic
abnormalities in CLL and MDS) come into wider
use, earlier intervention may also affect the natural
history of disease. In addition, even in the absence of
a true survival benefit, there are other favorable
outcomes that may result from prompt diagnosis and
referral. These possibly include improvements in
quality of life, reduced anxiety, access to educational
resources and amelioration of complications.
Our review has limitations. First, due to the
paucity of articles focusing on hematologic malig-
nancies, it was not feasible to perform a formal meta-
analysis or even systematic review with respect to the
magnitude of effects seen. Second, many of the
studies were descriptive rather than analytical,
although this is a result not of our methods but of
the quality of the available literature. Third, many of
the studies reported were performed in centralised
health care systems, which arguably have only
modest relevance to the United States, where a large
number of patients are uninsured and/or self-
referred. Finally, due to its very nature, our type of
review is open to the potential bias of selected papers,
selected extraction of data from these papers, and the
authors’ experiences of delay and its possible effects,
which is only partially ameliorated by our efforts to
include authors with differing areas of clinical
expertise (e.g. oncology, hematology and primary
care) and from varying disciplines (e.g. nursing,
medical and behavioral).
In summary, delays in referral and diagnosis for
patients with chronic hematologic malignancies may
be significant, may occur along different steps in the
pathway towards receiving treatment, and are likely
affected by patient and provider characteristics (as
well as the interaction between the two). Relatively
little information exists on the extent of diagnostic
and treatment delays for patients with hematologic
malignancies (especially for CLL and MDS). Addi-
tional studies to elicit the contributors of delay, the
outcomes associated with delay, and interventions to
increase PCP awareness and decrease delay are
needed.
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